Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • LinkedIn
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Arteriosclerosis, Thrombosis, and Vascular Biology

  • My alerts
  • Sign In
  • Join

  • Facebook
  • LinkedIn
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Vascular Biology

Thromboxane A2/Prostaglandin H2 Receptor Activation Mediates Angiotensin II–Induced Postischemic Neovascularization

Frédéric Michel, Jean-Sébastien Silvestre, Ludovic Waeckel, Stefano Corda, Tony Verbeuren, Jean Paul Vilaine, Michel Clergue, Micheline Duriez, Bernard I. Levy
Download PDF
https://doi.org/10.1161/01.ATV.0000201969.93348.74
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:488-493
Originally published February 16, 2006
Frédéric Michel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Sébastien Silvestre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ludovic Waeckel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefano Corda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tony Verbeuren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Paul Vilaine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Clergue
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Micheline Duriez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard I. Levy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading
  1. Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint

    Figure 1. A, Quantitative evaluation of TXB2 content in plasma. Quantitative evaluation of microangiography (B) and foot perfusion (C) 21 days after femoral artery occlusion. Values are mean±SEM (n=7). **P<0.01 vs sham-operated nonischemic mice. ††P<0.01 vs control ischemic mice. Sham indicates untreated sham-operated mice without hindlimb ischemia; Isch+ no treatment, untreated mice with hindlimb ischemia; Isch + S18886(5), mice with hindlimb ischemia treated with S18886 at 5 mg/kg per day; Isch + S18886(10), mice with hindlimb ischemia treated with S18886 at 10 mg/kg per day; Isch + Ram(10), mice with hindlimb ischemia treated with ramatroban at 10 mg/kg per day; and Isch + Asp, mice with hindlimb ischemia treated with aspirin at 30 mg/kg per day.

  2. Figure2
    • Download figure
    • Open in new tab
    • Download powerpoint

    Figure 2. Quantitative evaluation of microangiography (A), capillary density (B, capillary appears in white, arrows indicating representative examples of fibronectin-positive capillaries), and paw perfusion (C) 21 days after femoral artery occlusion. Values are mean±SEM. n=7 per group. *P<0.05 vs control ischemic mice. †P<0.05 vs Ang II-treated (0.3 mg/kg per day) ischemic mice. Cont indicates untreated mice with hindlimb ischemia; Ang II, mice with hindlimb ischemia treated with Ang II; Ang II + S 18886, mice with hindlimb ischemia treated with Ang II and S18886 at 10 mg/kg per day; Ang II + Ram, mice with hindlimb ischemia treated with Ang II and ramatroban at 10 mg/kg per day; Ang II + Asp, mice with hindlimb ischemia treated with Ang II and aspirin (30 mg/kg per day); Ang II + Cand, mice with hindlimb ischemia treated with Ang II and the AT1 receptor blocker candesartan (20 mg/kg per day); Isch, ischemic leg; N.Isch, nonischemic legs.

  3. Figure3
    • Download figure
    • Open in new tab
    • Download powerpoint

    Figure 3. A, Representative photomicrograph and quantitative evaluation of Mac-3–positive cells in ischemic tissue. B, Representative Western blot and quantitative evaluation of VEGF-A protein content. As a protein loading control, membranes were stripped, incubated with a goat polyclonal antibody directed against total actin. Values are mean±SEM, n=5 per group. *P<0.05 vs control ischemic mice. †P<0.05 vs Ang II-treated ischemic mice. Cont indicates untreated mice with hindlimb ischemia; Ang II, mice with hindlimb ischemia treated with Ang II; Ang II + S 18886, mice with hindlimb ischemia treated with Ang II and S18886 at 10 mg/kg per day; Ang II + Ram, mice with hindlimb ischemia treated with Ang II and ramatroban at 10 mg/kg per day; Ang II + Asp, mice with hindlimb ischemia treated with Ang II and aspirin (30 mg/kg per day); Ang II + Cand, mice with hindlimb ischemia treated with Ang II and the AT1 receptor blocker candesartan (20 mg/kg per day); Isch, ischemic leg.

Back to top
Previous ArticleNext Article

This Issue

Arteriosclerosis, Thrombosis, and Vascular Biology
March 2006, Volume 26, Issue 3
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Thromboxane A2/Prostaglandin H2 Receptor Activation Mediates Angiotensin II–Induced Postischemic Neovascularization
    Frédéric Michel, Jean-Sébastien Silvestre, Ludovic Waeckel, Stefano Corda, Tony Verbeuren, Jean Paul Vilaine, Michel Clergue, Micheline Duriez and Bernard I. Levy
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:488-493, originally published February 16, 2006
    https://doi.org/10.1161/01.ATV.0000201969.93348.74

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Arteriosclerosis, Thrombosis, and Vascular Biology.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Thromboxane A2/Prostaglandin H2 Receptor Activation Mediates Angiotensin II–Induced Postischemic Neovascularization
    (Your Name) has sent you a message from Arteriosclerosis, Thrombosis, and Vascular Biology
    (Your Name) thought you would like to see the Arteriosclerosis, Thrombosis, and Vascular Biology web site.
  • Share on Social Media
    Thromboxane A2/Prostaglandin H2 Receptor Activation Mediates Angiotensin II–Induced Postischemic Neovascularization
    Frédéric Michel, Jean-Sébastien Silvestre, Ludovic Waeckel, Stefano Corda, Tony Verbeuren, Jean Paul Vilaine, Michel Clergue, Micheline Duriez and Bernard I. Levy
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:488-493, originally published February 16, 2006
    https://doi.org/10.1161/01.ATV.0000201969.93348.74
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Arteriosclerosis, Thrombosis, and Vascular Biology

  • About ATVB
  • Instructions for Authors
  • AHA CME
  • Meeting Abstracts
  • Permissions
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Contact the Editorial Office:
email: atvb@atvb.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured